Find a Tender · Contract
Ustekinumab
A public procurement published by Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts) via Find a Tender.
- —
- Award value
- £6.1m
- Tender value
- 6
- Suppliers
- 6
- Awards
- 2
- Notices
- Contract
- Stage
Overview
Ustekinumab
Key details
- Source
- Find a Tender
- Lifecycle stage
- Contract
- Status
- active
- CPV classification
- 33600000 — Pharmaceutical products
- Currency
- GBP
- Total award value
- —
- Tender value
- £6,069,376
- First published
- 18 Jul 2024
- Last updated
- 4 Apr 2025
Awards
6 awards recorded on this procurement.
| Supplier | Companies House | Awarded | Status | Value |
|---|---|---|---|---|
| Celltrion Healthcare Uk Ltd | — | — | active | — |
| Sandoz Ltd | 01547204 | — | active | — |
| Thornton & Ross Ltd | 00185947 | — | active | — |
| Accord UK Ltd | 00079585 | — | active | — |
| Amgen Ltd | 02354269 | — | active | — |
| Janssen Ltd | — | — | active | — |
Notice timeline
Every published notice in this procurement's lifecycle.
All suppliers
Frameworks & programmes
FAQs about this procurement
Who is the buyer for "Ustekinumab"?
Ustekinumab is a UK public-sector procurement published by Velindre NHS Trust, NHS Shared Services Partnership - Procurement Services (on behalf of All Wales Health Boards and Trusts) via Find a Tender.
Has "Ustekinumab" been awarded?
Yes — 6 awards are recorded, with a reported total value of £6,069,376. The current lifecycle stage is "Contract".
Which suppliers are involved in "Ustekinumab"?
6 suppliers are linked: Celltrion Healthcare Uk Ltd, Sandoz Ltd, Thornton & Ross Ltd, Accord UK Ltd, Amgen Ltd, Janssen Ltd.
What is "Ustekinumab" worth?
The reported tender value is £6,069,376.
When was "Ustekinumab" published?
It was first published on 18 Jul 2024 and last updated on 4 Apr 2025, across 2 notices.
Track procurements like this one
Enable monitors the entire UK public-contract pipeline — get alerts on buyers, suppliers and frameworks that matter to you.
Get in touch with Enable